Position in EXEL
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$23,784,676
+$23,536,646 QoQ
Shares Held
437,138
+7459.0% QoQ
Ownership
0.176%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#81
of 751 holders
Holding Since
Dec 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Baird Financial Group, Inc. holds $221,188,371 across 29 Biotechnology names. EXEL ranks #4 (10.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ONC |
BeOne Medicines Ltd.
|
368,978 | $105,147,660 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
52,845 | $32,950,970 | |
| 3 | INCY |
Incyte Corp
|
224,855 | $25,489,561 | |
| 4 | EXEL |
Exelixis, Inc.
This page
|
437,138 | $23,784,676 | |
| 5 | INVA |
Innoviva, Inc.
|
274,391 | $6,231,419 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
|
38,672 | $2,880,290 | |
| 7 | ASND |
Ascendis Pharma A/S
|
10,735 | $2,863,239 | |
| 8 | LGND |
Ligand Pharmaceuticals Inc
|
8,550 | $2,702,569 |
All Filings in EXEL
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $23,784,676 | 437,138 | Shares | Defined | 2026-08-12 | |
| 2026-03-31 | $248,030 | 5,783 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $292,387 | 6,671 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $307,352 | 7,442 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $258,615 | 5,867 | Shares | Defined | 2025-08-13 | |
| 2024-06-30 | $994,026 | 44,238 | Shares | Defined | 2024-08-14 | |
| 2024-03-31 | $843,789 | 35,558 | Shares | Defined | 2024-05-14 | |
| 2023-12-31 | $752,062 | 31,349 | Shares | Defined | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||